<DOC>
	<DOC>NCT01965080</DOC>
	<brief_summary>A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma Hypothesis: Treatment With Exemestane can give a response rate of at least 30%</brief_summary>
	<brief_title>Exemestane in Advanced and Recurrent Endometrial Carcinoma</brief_title>
	<detailed_description>Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated With Exemestane tablets 25 mg daily. Patients were grouped according to estrogen receptor status.</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Advanced or recurrent endometrial cancer not considered for treatment modalities apart from hormonal treatment Endometrioid histology Age above 18 years Post menopausal status Performance status 02 Informed consent Congestive heart disease grade III.IV History of thromboembolic signs Other primary hormonal therapy Patients With symptomatic brain metastasis Severe hepatic or renal impairment Pregnancy, lactation or child bearing potential without adequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Endometrial cancer</keyword>
</DOC>